"RSV is a common viral infection that affects the lungs and upper airways. While most people recover without medical care, RSV can cause serious illness especially in infants, young children and older adults. Every winter in Ireland, more than 7,000 people are diagnosed with RSV, with historically a large number of young children requiring admission to hospital, especially infants aged less than one year."
"Providing immunisation to all infants would cost the HSE an additional €50 to €60m over the first five years, while offering immunisation to adults aged 80 years and older would amount to an additional €70m. Hiqa was asked to complete this assessment to inform a long-term policy decision by the Minister for Health regarding an RSV immunisation strategy for infants and older adults in Ireland."
"RSV immunisation is safe and would significantly reduce the RSV burden on families and on healthcare services. However, these new RSV immunisation products are expensive. The HSE would have to negotiate considerable price reductions in order for any of the immunisation strategies reviewed to represent an efficient use of HSE resources."
RSV is a common viral infection affecting the lungs and upper airways and can cause serious illness in infants, young children and older adults. Every winter in Ireland more than 7,000 people are diagnosed with RSV, and a historically large number of children, especially infants under one year, require hospital admission. RSV immunisation is safe and provides infants protection for a single RSV season and older adults protection for up to three seasons, with benefits decreasing over time. A national immunisation programme would incur substantial costs: vaccinating all infants would add €50–60m over five years and vaccinating adults aged 80+ would add €70m. Considerable vaccine price reductions would be needed for these strategies to represent efficient HSE resource use.
Read at Irish Independent
Unable to calculate read time
Collection
[
|
...
]